CI
DMAC icon

Corient IA’s DiaMedica Therapeutics DMAC Stock Holding History

Corient IA’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Sell
35,000
-25,000
-42% -$154K 0.23% 142
2026
Q1 		$406K Buy
+60,000
New +$475K 0.38% 90
2025
Q4 		– Sell
-132,500
Closed -$910K – 214
2025
Q3 		$910K Buy
+132,500
New +$719K 0.68% 33

Other funds holding DMAC

Cooperman Leon G
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Corient IA's DMAC Position: Q2 2026 in Review

Corient IA reduced its DiaMedica Therapeutics (DMAC) stake by 42% in Q2 2026, selling an estimated $154K and leaving 35,000 shares worth $246K. The position accounts for 0.23% of the portfolio, ranked #142.

Corient IA first reported a position in DMAC in Q3 2025 and has held it in 3 quarters since. The position peaked at $910K in Q3 2025. 88 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Corient IA held 35,000 shares of DiaMedica Therapeutics worth $246K as of Q2 2026.
  • Corient IA sold 25,000 DiaMedica Therapeutics shares in Q2 2026, an estimated $154K.
  • DiaMedica Therapeutics made up 0.23% of Corient IA's portfolio in Q2 2026, its #142 holding.
  • Corient IA first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Corient IA's DiaMedica Therapeutics position peaked at $910K in Q3 2025.
  • 88 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Corient IA's 13F filing for Q2 2026, filed 12 Aug 2026.